Kornimate/medical-research-clean huggingface dataset:
differential expression of cd200 in b-chronic lymphoproliferative disorders by multicolour flow cytometry

Conditions: Neoplasms

Summary: the investigator's goals in this study are to assess : 1. differential expression of cd200 by using flow cytometric immune-phenotyping in broad range of patients with b-chronic lymphoproliferative disorders (b-clpd) 2. role of cd200 in diagnosis , classification and potential value in differential diagnosis 3. cd200 expression level at different anatomic sites

b-chronic lymphoproliferative disorders (b-clpds) are heterogeneous group of disorders with variable clinical presentations and outcomes. they are classified into : chronic lymphocytic leukaemia (cll), b-cell prolymphocytic leukaemia (b-pll), hairy cell leukaemia (hcl), and mantle cell lymphoma (mcl), marginal zone lymphoma (mzl), follicular lymphoma (fl) and lymphoplasmacytic lymphoma/waldenström macroglobulinaemia (lpl/wm) in leukaemia phase. characterization of clpds by immunophenotyping (ipt) has become an important and widely used method in hematology. immunophenotyping is indispensable for the diagnosis of b-clpds through recognition of restricted light chain expression and characteristic phenotypes of separate entities. immunophenotypic characterization of lymphoid neoplasms is important for diagnosis, sub-classification, and staging and can also play a role in monitoring minimal residual disease. however, the differential diagnosis may be difficult to resolve in some cases, for example, between b-cell neoplasms with full or partial cd5 expression. cd200 has recently been identified as a potentially useful antigen for flow cytometric immunophenotyping of lymphoid neoplasms, particularly those of the b lineage. cd200 belongs to the immunoglobulin superfamily and is composed of a light chain-like structure with two extracellular variable- and constant-like domains followed by a transmembrane segment and a cytoplasmic tail.5 cd200 is expressed by various cell types, including b cells, a subset of t cells (including activated t cells), thymocytes, endothelial cells, and neurons . cd200 generates an immunosuppressive signal by binding to its cognate receptor, cd200 receptor 1 (cd200r1) , which is expressed specifically in granulocytes and monocytes and in a subset of t cells. cd200 appears to play a role in the regulation of antitumor activity and these findings are the basis for ongoing clinical trials using anti-cd200 therapy for chronic lymphocytic leukemia (cll)

Eligibility criteria:
inclusion criteria: * all newly diagnosed patients with b-chronic lymphoproliferative disorders exclusion criteria: * 1) patient refusal 2) patients diagnosed t-cell non-hodgkins lymphoma 3) patients receiving chemo and/or radiotherapy 4) patients on steroid therapy for any other cause 5) patients receiving any immunosuppressive drugs

Keywords: chronic lymphoproliferative disorders
the safety and effectiveness of latuda® post-marketing surveillance in the treatment of chinese schizophrenia patients

Conditions: Schizophrenia

Summary: it's a prospective, non-interventional, observational post-marketing surveillance..

it's a prospective, non-interventional, observational post-marketing surveillance, the aim of the surveillance is to observe the safety and overall effectiveness of latuda® in the treatment of chinese patients with schizophrenia for 12 weeks in real clinical practice, as well as the dose of latuda® for monotherapy or combination therapy.

Eligibility criteria:
inclusion criteria: * schizophrenia patients who begin to receive latuda® exclusion criteria: * no exclusion criteria
hydroxylated polymethoxy flavones solid dispersion in treatment of periodontitis

Conditions: Inflammatory Disease; Periodontal Diseases

Summary: periodontitis is a serious gum infection that damages the soft tissue and, without treatment, can destroy the bone that supports your teeth. hydroxylated poly methoxy flavones are a combination of naturally occurring flavonoids extracted from the orange peel and exert anti-inflammatory, antibacterial, and antifungal activity however, this extract is poorly soluble and poorly absorbable. in this work, this extract was formulated as a solid dispersion formulation to enhance its biological activity and then incorporated into a gel base and used in the treatment of periodontitis after clinical debridement.

in the study, there are 3 groups; the first one first one received plain sodium carboxymethylcellulose. group ii received chlorhexidine gel. groupiii received hydroxylated poly methoxy flavones solid dispersion incorporated into sodium carboxymethylcellulose gel. in all groups, there is clinical debridement before injection of gels.

Eligibility criteria:
inclusion criteria: * patients with periodontitis stage i-ii * free from any systemic disorders. * no mobility - non-smokers - no parafunctional habits. * each patient with minimum three periodontitis sites ( split-mouth study) exclusion criteria: * smokers. * patients with diabetes, and hypertension.
prospective, randomised, single-blinded, monocentric clinical study to compare postoperative analgesia and outcome after combined paravertebral and intrathecal versus thoracic epidural analgesia for thoracotomy

Conditions: Pain, Postoperative

Summary: the purpose of this study is to compare whether epidural analgesia would provide equal analgesia than combining intrathecal opioids with thoracic paravertebral local anesthetics.

thoracotomy is an invasive surgical procedure, which is mainly performed in patients with pre-existing lung disease such as lung cancer or chronic obstructive pulmonary disease. pain after thoracotomy is considered the most intense acute postoperative pain, adversely affecting the ability to cough, deep breathing, and lung function, resulting in respiratory complications and delayed recovery. the adverse effects can be further aggravated by occurrence of chronic post-thoracotomy pain. thoracic epidural analgesia is often recommended as the gold standard for the relief of acute post-thoracotomy pain. thoracic paravertebral blockade or intrathecal opioid analgesia has also been shown to be efficacious for pain relief. since there is no ideal single regional technique for pain relief after thoracotomy an alternative method maybe the combination of low-dose intrathecal morphine and sufentanil plus continuous thoracic paravertebral analgesia with local anesthetics. we therefore hypothesized that combining intrathecal sufentanil and morphine with thoracic paravertebral applicated ropivacaine would provide equal analgesia compared to thoracic epidural analgesia with ropivacaine and sufentanil. we further speculate that this new regimen would have a lower incidence of typical side effects due to tea, such as block failure, hypotension or urinary retention.

Eligibility criteria:
inclusion criteria: * sex: male/female * age: 18 - 75 years * informed consent of the patient * elective thoracotomy * two chest drains exclusion criteria: * contraindications against the use of regional techniques: known allergy to local anesthetics * infection around the puncture site * coagulation disorders * drug abuse * emergency surgery * pregnancy

Keywords: thoracotomy pain therapy thoracic paravertebral blockade intrathecal opioids thoracic epidural analgesia analgesia after thoracotomy
study on serum cystatin c and pet-dat in patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: to investigate the relationship between serum cystatin c and dopamine receptor(dat) loss in patients with parkinson's disease(pd)

number of people suffered from parkinson disease (pd) is increasing every year. pet imaging of dopamine transport receptors（dat） serves as the gold standard for the diagnosis and monitoring of pd development. however, due to high costs and radiation reasons, it is not suitable for long-term follow-up. serum cystatin c can be easily obtained and cheap as an indicator. in recent years, studies have gradually found that it is related to the progression of h\&y staging of parkinson's disease. to this extent, we want to further explore whether it can reflect the loss of dat in the brain. explore whether it can partially replace the role of dat imaging for future clinical evaluation.

Eligibility criteria:
inclusion criteria: * patients aged between 20 and 80 years and whose laboratory results included the levels of serum cystatin c within a month from the pet-dat were recruited. exclusion criteria: * to make the study cohort more homogeneous, pd patients with either a long-standing duration (≥5 years) or advanced hoehn and yahr (h\&y) staging (≥3) were excluded.

Keywords: cystatin c, pet-dat
evaluate the safety, tolerability, immunogenicity and efficacy of ub-311 in mild alzheimer's disease (ad) patients

Conditions: Alzheimer's Disease

Summary: the purpose of this phase iia study is to determine whether the ad immunotherapeutic vaccine (ub-311), targeting the amyloid beta peptide (n-terminal amino acids, 1-14), is safe and immunogenic in mild ad patients. in addition, the efficacy profiles will be evaluated as the secondary endpoint.


Eligibility criteria:
inclusion criteria: * diagnosis of mild alzheimer's disease * mini-mental state examination (mmse) scores between 20 and 26 (inclusive) * clinical dementia rating (cdr) scores of 0.5 or 1 * other inclusion criteria apply exclusion criteria: * clinically significant neurological disease other than alzheimer's disease * major psychiatric disorder * severe systemic disease * serious adverse reactions to any vaccine * other exclusion criteria apply
korean life-style modification effects on blood pressure

Conditions: Prehypertension; Hypertension

Summary: in hypertension, lifestyle modification has been proven to be effective in reducing blood pressure while decreasing the risk of cardiovascular disease. the dietary approaches to stop hypertension(dash) diet, sodium restriction and exercise has been shown to reduce systolic blood pressure by 8-14mmhg, 2-8mmhg and 4-9mmhg, respectively. the dash-sodium diet has been shown to have additional systolic blood pressure lowering effect of 7.2mmhg, which is equal to adding one antihypertensive drug. however, as the dietary pattern is different in the korean population, the investigators cannot implement the data from western countries directly to the korean population. for example, the consumption of dairy products is much smaller in the korean population when compared to the western population. therefore, the effectiveness of dash-sodium diet and exercise on blood pressure lowering in the korean population is not well defined. in this study, the investigators sought to determine the effectiveness of the dash-salt diet and dash-salt diet plus exercise on brachial blood pressure lowering. the study will be performed on untreated prehypertension patients and uncontrolled hypertensive patients undergoing anti hypertensive treatment with blood pressure measured between 140-159mmhg/90-99mmhg at the time of enrollment.


Eligibility criteria:
inclusion criteria: 1. adult age \>20 2. if the subject not taken antihypertension, sbp and dbp must be the following result. sbp: 120\~159 mmhg , dbp: 80-99 mmhg 3. if the subject taken antihypertension, sbp and dbp must be the following result. sbp: 140-159mmhg ,dbp: 90-99 mmhg 4. bmi 18.5kg/m²\~44kg/m² 5. patients voluntarily agreed to participate in this study 6. non-pregnant women, non-breastfeeding women, women of childbearing age must be negative in hcg result. (not taking an oral contraceptive) exclusion criteria: 1. if the subject not taken antihypertension, sbp and dbp must be the following result. * 120\>sbp\>159 mmhg, 80\>dbp\>99 mmhg 2. if the subject taken antihypertension, the number of three or more antihypertensive 3. if the subject taken antihypertension, sbp and dbp must be the following result. * 140\>sbp\>159 mmhg, 90\>dbp\>99 mmhg 4. having the target organ disease, the following disease. * heart disease: lt.venricular hyperplasia, angina, mi, coronary revascularization, heart failure * brain disease: stroke, tia, dementia * kidney disease: * pheripheral artery disease * retinopathy disease 5. cancer, liver disease 6. regular drinking alcohol above 14 cup of during 1 week. 7. pregnant women, women of childbearing age tested positive in hcg result. 8. pregnant women, breastfeeding women 9. screening test result cs 10. illiteracy, a foreigner, the person who can't read the consent 11. the person who had participated other study in 3 months. 12. the person who inappropriate to participate

Keywords: prehypertension, hypertension
establishment of a patient library in patients with pruritus sine materia

Conditions: Pruritus; Chronic Pruritus; Itch

Summary: very little is currently known about the pathophysiology of pruritus sine materia according to the etiology. the creation of this cohort should make it possible to improve our clinical and biological knowledge according to the etiology, by collecting blood, skin, feces, and clinical data.

at inclusion, 52.5 ml of blood will be collected, then an additional skin biopsy and a skin swab. five questionnaires will be filled in by the patient. at 6 months, then every years for 5 years, the same 5 questionnaires will be collected as well as the clinical data. however, no more biological samples will be collected.

Eligibility criteria:
inclusion criteria: * diagnosis of pruritus sine materia * collection of consent * adult exclusion criteria: - refusal to participate in the study
combination of alemtuzumab and rituximab at low-doses in refractory chronic graft-versus-host disease

Conditions: Graft vs Host Disease

Summary: the purpose of this study is to determine whether low-doses alemtuzumab and rituximab combination are effective in the treatment of chronic graft-versus-host disease (gvhd) after first-line therapy failure.

graft-versus-host disease (gvhd) is the most common long-term complication in patients who underwent allogeneic transplantation. first-line therapy for chronic gvhd is based on immunosuppressive agents (usually cyclosporine and corticosteroids) achieving satisfactory response in around 30% of patients. there is no ideal second-line treatment for chronic gvhd; however, numerous studies have been published with therapeutic options such as alemtuzumab (anti-cd52) and rituximab (anti-cd20). this is a prospective, longitudinal, nonrandomized study in which alemtuzumab and rituximab will be administered at low-doses to patients with refractory chronic gvhd. clinical response will be evaluated based on the working group report 2006, published by the national institute of health consensus. follow-up sessions will be weekly for four weeks, every two weeks until achieve response, and finally every four weeks.

Eligibility criteria:
inclusion criteria: * patients with chronic graft-versus-host disease. * patients over 18 years old. * patients who received first-line treatment with no response (failure), relapse or steroid dependance. exclusion criteria: * patients with active bacterial or viral infections. * patients with hematologic disease progression. * patient's intolerance to drugs.

Keywords: chronic graft vs host disease alemtuzumab rituximab low-dose alemtuzumab and rituximab combination
mangement of spine fracture

Conditions: Spine Fracture

Summary: each year, there are approximately 5 million new vertebral fractures worldwide1. most of these fractures involve the thoracolumbar or lumbar spines. the thoracolumbar junction, due to its mechanical transition zone, and the lumbar spine, due to its absence of stabilizing articulations with the ribs, lordotic posture and more sagittal oriented facet joints, are vulnerable for involvement in spinal injuries2. burst fractures occurs frequently in high-energy traumas which are most commonly associated with falls and traffic accidents.3


Eligibility criteria:
inclusion criteria: * 1-skeletally mature patients (18yrs and older). 2-thoracolumbar fractures. exclusion criteria: * 1-skeletally immature patients. 2-pathological fractures.
cardiac magnetic resonance tomography for heart failure with preserved ejection fraction

Conditions: Heart Failure, Diastolic

Summary: the diagnosis of heart failure with preserved ejection fraction has so far been made primarily according to criteria determined by echocardiography, or invasively by measuring the left ventricular filling pressures. increasingly, cmr is also evaluated with regard to the diagnosis of cardiac insufficiency with preserved pump function.however, it is still unclear which parameters can be used meaningfully for diagnostics.to answer this question, the investigators want to retrospectively evaluate data collected from patients with a clinical indication for cmr and coronary angiography.

heart failure with preserved pump function is a common disease that is associated with a high level of suffering for the patient. the diagnosis has so far been made primarily according to criteria determined by echocardiography, or invasively by measuring the left ventricular filling pressures. with its high spatial resolution and the possibility of tissue-specific diagnostics, cardiac mri (cmr) offers outstanding possibilities in cardiac imaging without exposing the patient to ionizing radiation. increasingly, cmr is also evaluated with regard to the diagnosis of cardiac insufficiency with preserved pump function. however, it is still unclear which parameters can be used meaningfully for diagnostics. there is evidence for a correlation with invasively increased lvedp, although the number of patients examined in the previous studies was still small. in addition, possible influences from medication and clinical parameters were not examined. to answer this question, the investigators want to retrospectively evaluate data collected from patients with a clinical indication. the significance of the study is that in the future cmr could supplement echocardiography in the diagnosis of hfpef and further reduce the need for invasive diagnostics.

Eligibility criteria:
inclusion criteria: * patients with cmr and left heart catheterization including lvedp measurement within the same month exclusion criteria: * severe valve dysfunction or pericardial/pleural disease * contraindictaion for cr or cath

Keywords: cardiac magnetic resonance magnetic resonance imaging lvedp
a study to evaluate the safety and efficacy of vx-371 in subjects with cystic fibrosis who are homozygous for the f508del-cftr mutation

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to evaluate the safety and efficacy of treatment with vx-371 in hypertonic saline compared to hypertonic saline alone in subjects with cystic fibrosis (cf) who are ≥12 years of age, homozygous for the f508del-cystic fibrosis transmembrane conductance regulator (cftr) mutation, and being treated with orkambi


Eligibility criteria:
inclusion criteria: * willing and able to use the delivery device as directed by the study manual. * confirmed diagnosis of cf, defined as a sweat chloride value ≥60 mmol/l by quantitative pilocarpine iontophoresis. * homozygous for the f508del cftr mutation. if the cftr screening genotype result is not received before randomization, a previous cftr genotype lab report may be used to establish eligibility. * percent predicted forced expiratory volume at one second (fev1) of ≥40 to \<90 percentage points adjusted for age, sex, and height according to the global lung initiative (gli) at the screening visit. * willing to discontinue physician-prescribed saline use. * female subjects of childbearing potential with a negative serum pregnancy test at the screening visit. exclusion criteria: * history of any comorbidity, which in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. * any clinically significant laboratory abnormalities at the screening visit that would interfere with the study assessments or pose an undue risk for the subject. * an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before day 1 (first dose of study drug). * a 12 lead ecg demonstrating qtcf \>450 msec at the screening visit. * history of solid organ or hematological transplantation. * used diuretics or renin-angiotensin aldosterone system antihypertensive drugs in the 28 days prior to screening or an anticipated need for any of these medications during the study. * ongoing or prior participation in an investigational drug study within 30 days of the screening visit. * inability to withhold short-acting, long-acting, or once-daily, long-acting bronchodilator use for 4, 12, or 24 hours prior to clinic visit, respectively. * history of significant intolerance to inhaled saline, or intolerance to the single dose of saline at screening * known hypersensitivity or history of intolerance to orkambi. * pregnant and nursing females. * subjects who have participated in parion sciences study nct02343445.
soluble cd95 ligand role in the pathophysiology of non-infectious active uveitis

Conditions: Non-Infectious Active Uveitis

Summary: the study aims at defining the role of soluble cd95 ligand in the physiopathology of the non-infectious uveitis. soluble cd95 ligand might have a prognostic interest as well as potential for the discovery of new therapeutic strategies

non-infectious active uveitis is a severe inflammatory ocular disease which can expose to the blindness. actually, the knowledge of the physiopathology of uveitis stay poorly. cd95 ligand (cd95-l) belongs to a tnf (tumor necrosis factors) receptor family. it knows to play a preponderant role to maintain the eye immune privilege. in particular conditions depending on immunologic environment, cd95-l has pro-inflammatory properties and can interact with th17 lymphocytes and neutrophils, two cells implicated in non-infectious uveitis. the hypothesis is that s-cd95-l levels might be a prognostic factor in non-infectious uveitis and the study of the molecular mechanisms involved could provide new therapeutic targets. this study will recruit 100 patients with non-infectious uveitis followed in bordeaux university hospital. among classical disease activity information, blood samples will be collected during to assess s-cd95-l. fundamental research will be realized on patients' sample to evaluate underlying molecular mechanisms. clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-cd95-l to describe their potential prognostic role. patients will be followed at regular intervals, accordingly to usual care.

Eligibility criteria:
inclusion criteria: * diagnosis of non-infectious uveitis according to the sun (standardization of the uveitis nomenclature) working group; * age ≥ 18 years; * being affiliated to health insurance, * willing to participate. exclusion criteria: * pregnant or breastfeeding women, * patient under legal protection measure , * poor understanding of the french language

Keywords: non infectious active uveitis soluble-cd95-ligand
a randomized controlled trial to evaluate the use of botox in breast reconstruction with tissue expanders

Conditions: Breast Cancer

Summary: investigation of whether injection of the pectoralis muscle with 100 units botulinum toxin during breast reconstruction with tissue expanders results in decreased pain using a blinded, randomized, controlled trial.


Eligibility criteria:
inclusion criteria: * bilateral mastectomy with immediate tissue expander reconstruction exclusion criteria: * unwilling to receive study injections

Keywords: tissue expanders botulinum toxin botox